Should I buy or sell Ensysce Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENSC shares. View ENSC analyst ratings or view top-rated stocks .

What is Ensysce Biosciences' stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Ensysce Biosciences' shares. Their ENSC share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 1,106.5% from the stock's current price. View analysts price targets for ENSC or view top-rated stocks among Wall Street analysts .

How have ENSC shares performed in 2024?

Ensysce Biosciences' stock was trading at $1.06 at the beginning of the year. Since then, ENSC stock has decreased by 45.3% and is now trading at $0.5802. View the best growth stocks for 2024 here .

Are investors shorting Ensysce Biosciences?

Ensysce Biosciences saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 17,500 shares, a decrease of 69.0% from the March 15th total of 56,500 shares. Based on an average daily volume of 1,450,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.6% of the shares of the stock are short sold. View Ensysce Biosciences' Short Interest .

When is Ensysce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ENSC earnings forecast .

How were Ensysce Biosciences' earnings last quarter?

Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced its quarterly earnings data on Friday, March, 15th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.27. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.53 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 1,024.79% and a negative net margin of 476.29%.

When did Ensysce Biosciences' stock split?

Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free ENSC Stock Alerts

$0.58

-0.05 (-7.93%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.58
▼
$0.66
50-Day Range: $0.58
▼
$1.14
52-Week Range: $0.58
▼
$7.20

Volume: 89,771 shs
Average Volume: 1.27 million shs
Market Capitalization: $4.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Ensysce Biosciences alerts:

Ensysce Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,106.5% Upside
$7.00 Price Target
Short Interest: Healthy
0.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.50) to ($2.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.30 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Ensysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ensysce Biosciences has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.60% of the float of Ensysce Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Ensysce Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ensysce Biosciences has recently decreased by 69.03%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ensysce Biosciences does not currently pay a dividend.
Dividend Growth
Ensysce Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENSC.

0.6

News and Social Media Coverage

Search Interest
Only 4 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
5 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.40% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ensysce Biosciences are expected to grow in the coming year, from ($2.50) to ($2.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ensysce Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ensysce Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Ensysce Biosciences Stock (NASDAQ:ENSC)

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.

ENSC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENSC Stock News Headlines

April 9, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

March 18, 2024 | investorplace.com

ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 15, 2024 | finance.yahoo.com

ENSC Striding Toward Opioid Replacement

March 15, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 | benzinga.com

Ensysce Biosciences Stock (NASDAQ:ENSC), Short Interest Report

February 21, 2024 | finance.yahoo.com

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

February 16, 2024 | finance.yahoo.com

ENSC: Investors Should Pay Attention

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 15, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

February 15, 2024 | finance.yahoo.com

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

February 13, 2024 | msn.com

Ensysce Biosciences falls on exercise of warrants for $4.7M gross proceeds

February 13, 2024 | finance.yahoo.com

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

February 6, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

February 6, 2024 | finance.yahoo.com

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

January 31, 2024 | finance.yahoo.com

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

January 25, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

January 25, 2024 | finance.yahoo.com

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

January 23, 2024 | seekingalpha.com

Ensysce rallies 22% on FDA update for overdose-resistant opioid

January 23, 2024 | finance.yahoo.com

Opioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why

January 23, 2024 | finance.yahoo.com

ENSC Announces Major FDA Designation

January 23, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

January 23, 2024 | finance.yahoo.com

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

January 17, 2024 | msn.com

Ensysce Biosciences files to sell common stock, warrants

January 8, 2024 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Issues 2024 Shareholder Letter

January 8, 2024 | finance.yahoo.com

Ensysce Biosciences Issues 2024 Shareholder Letter

December 19, 2023 | finance.yahoo.com

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

See More Headlines

Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ENSC
CUSIP: N/A
CIK: 1716947
Web: ensysce.com
Phone: 858-263-4196
Fax: N/A
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +1,026.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,610,000.00
Net Margins: -476.29%
Pretax Margin: -476.29%
Return on Equity: -1,024.79%
Return on Assets: -262.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.69
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $2.23 million
Price / Sales: 2.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.21) per share
Price / Book: -2.96

Miscellaneous

Outstanding Shares: 7,329,000
Free Float: 3,467,000
Market Cap: $4.55 million
Optionable: Not Optionable
Beta: 0.77

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. D. Lynn Kirkpatrick Ph.D. (Age 67)
President, CEO & Director
Comp: $414.77k
Mr. Geoffrey Birkett (Age 61)
Chief Commercial Officer
Comp: $322k
Dr. Jeffrey Millard Ph.d. (Age 48)
Chief Operating Officer
Dr. William K. Schmidt Ph.D. (Age 73)
Chairman of Clinical Advisory Board & Chief Medical Officer
Dr. Linda Pestano Ph.D. (Age 54)
Chief Development Officer

Key Competitors

View All Competitors

ENSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Ensysce Biosciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENSC shares.
View ENSC analyst ratings or view top-rated stocks.
What is Ensysce Biosciences' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month target prices for Ensysce Biosciences' shares. Their ENSC share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 1,106.5% from the stock's current price.
View analysts price targets for ENSC or view top-rated stocks among Wall Street analysts.
How have ENSC shares performed in 2024?: Ensysce Biosciences' stock was trading at $1.06 at the beginning of the year. Since then, ENSC stock has decreased by 45.3% and is now trading at $0.5802.
View the best growth stocks for 2024 here.
Are investors shorting Ensysce Biosciences?: Ensysce Biosciences saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 17,500 shares, a decrease of 69.0% from the March 15th total of 56,500 shares. Based on an average daily volume of 1,450,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.6% of the shares of the stock are short sold.
View Ensysce Biosciences' Short Interest.

When is Ensysce Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ENSC earnings forecast.
How were Ensysce Biosciences' earnings last quarter?: Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced its quarterly earnings data on Friday, March, 15th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.27. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.53 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 1,024.79% and a negative net margin of 476.29%.
When did Ensysce Biosciences' stock split?: Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
How do I buy shares of Ensysce Biosciences?: Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENSC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Ensysce Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ensysce Biosciences Stock (NASDAQ:ENSC)

ENSC Stock Price History

ENSC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ENSC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™